Entries |
Document | Title | Date |
20080206228 | Pharmaceutical Compositions Containing Hyaluronic Acid and Collagenase for the Topical Treatment of Wounds, Burns and Ulcers - The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars. | 08-28-2008 |
20090010918 | METHODS FOR TREATMENT USING COLLAGENASE - Methods for treatment by collagenase injections are provided, which are effective in dissolving and lysing a collagenase septa network to treat carpal tunnel, plantar fasciitis and lateral epicondylitis conditions. The methods treat such conditions by injecting or otherwise delivering purified collagenase to the afflicted region of the patient, as well as use of collagenase for manufacture of a medicament for such conditions. | 01-08-2009 |
20090074744 | USE OF COLLAGENASE TO FACILITATE GUIDE WIRE CROSSING IN TOTAL ARTERIAL OCCLUSIONS - The use of a collagenase containing formulation for degrading collagen within an occlusive atherosclerotic plaque in a chronic fibrotic occlusion, chronically occluded animal tube or cavity. A medical-related apparatus is provided comprising a medical-related device having provided thereto a therapeutic amount of a collagen degrading composition comprising a proteiolytic enzyme containing formulation A method is provided for treating chronically occluded animal tubes and cavities by administering a therapeutic effective amount of a proteolytic enzyme-containing formulation adjacent to an occluding atherosclerotic plaque, waiting for a pre-angioplasty waiting period, followed by crossing the plaque with an angioplasty guide wire. | 03-19-2009 |
20090123454 | METHODS FOR TREATING ADHESIVE CAPSULITIS - The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the invention relates to methods of treating or preventing adhesive capsulitis, or frozen shoulder, in a patient in need of such treatment comprising injecting or otherwise delivering an effective amount of collagenase to the collagenous adhesions in the shoulder. The invention also relates to the use of collagenase in the manufacture of a medicament to treat adhesive capsulitis. | 05-14-2009 |
20090196866 | Pharmaceutical composition containing an iron-binding agent - A pharmaceutical composition is disclosed. In at least one embodiment, a pharmaceutical drug is linked via a peptide linker to an iron-binding agent, for example an iron-binding protein, with the iron-binding agent in turn being bound to an iron-containing magnetic particle. The peptide linker has a protease recognition sequence, i.e. it may be cleaved at said protease recognition sequence by a protease, thereby enabling the pharmaceutical drug to be released locally. The pharmaceutical composition is suitable for magnetic drug targeting. | 08-06-2009 |
20090202517 | AGENTS FOR IMPROVING INFLAMMATORY BOWEL DISEASE - The present inventors discovered for the first time that intestinal inflammation could be efficiently suppressed by suppressing the production or accumulation of chondroitin sulfate proteoglycans. Specifically, inflammation in the large intestine can be suppressed by using siRNA to suppress the expression of versican, which is one of the chondroitin sulfate proteoglycans. Compounds used as siRNA, such as nucleic acids, can be used as effective agents for suppressing intestinal inflammation. Furthermore, the above finding also suggests that such intestinal inflammation-suppressing agents can be found by screening for compounds that suppress the production or accumulation of chondroitin sulfate proteoglycans. | 08-13-2009 |
20090214513 | MAMMALIAN EXPRESSION SYSTEMS - The present invention features mammalian expression systems with improved production yields, and method of using these systems to produce desired proteins. In one embodiment, the expression systems of the present invention comprise genetically-engineered mammalian host cells cultured in a medium that contains an effective amount of heparin or heparin-like molecules. The presence of heparin or heparin-like molecules significantly increases protein production by the cultured cells. The present invention also features the use of constitutively-active components of FGFR-I-mediated signal transduction pathways to improve protein production by cultured mammalian cells. Co-expression of such a component with a protein of interest markedly increases the production yield of the protein of interest. | 08-27-2009 |
20090274683 | ADAMTS13 GENES AND PROTEINS AND VARIANTS, AND THERAPEUTIC COMPOSITIONS AND METHODS OF UTILIZING THE SAME - The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13. | 11-05-2009 |
20090304672 | ADAMTS13 GENES AND PROTEINS AND VARIANTS, AND THERAPEUTIC COMPOSITIONS AND METHODS OF UTILIZING THE SAME - The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13. | 12-10-2009 |
20090304673 | Method of Treatment of Inflammatory Diseases - The present invention relates to a method of treatment of an inflammatory disease, in particular sepsis, in particular sepsis caused by gram-positive bacteria, wherein the method comprises the step of administering to a subject in need thereof a sufficient amount of bacterial cell wall degrading enzymes. The present invention relates further to pharmaceutical compositions comprising bacterial cell wall degrading enzymes. | 12-10-2009 |
20090317375 | VON WILLEBRAND FACTOR (VWF) INHIBITORS FOR TREATMENT OR PREVENTION OF INFARCTION - This invention relates to methods for treating or preventing an infarction by administering to a patient in need thereof a compound capable of suppressing the expression or activity of the von Willebrand Factor (VWF). Thus, the invention relates to the use of a pharmaceutically effective amount of a VWF inhibitor, such as ADAMTS13, for the preparation of a medicament for treating conditions known to involve infarction to reduce or eliminate the symptoms and effect of an infarction. | 12-24-2009 |
20100021450 | Lys K Endolysin Is Synergistic with Lysostaphin Against MRSA - Multi-drug resistant superbugs are a persistent problem in modern health care. LysK is a staphylococcal bacteriophage endolysin from the phage K. It is a peptidoglycan hydrolase enzyme that can lyse many staphylococcal strains and thus is a potent antimicrobial against | 01-28-2010 |
20100040598 | KIT OF PARTS COMPRISING AN ACID LABILE AND AN ACID RESISTANT PHARMACEUTICALLY ACTIVE INGREDIENT - The present invention relates to a combination of pharmaceutical compositions adapted for oral administration one of which comprises a pharmaceutically active ingredient being acid resistant, and the other of which comprises a pharmaceutically active ingredient being acid labile. Said combination is in the form of a kit of parts which is administered in such way as to use food intake to optimize absorption of both the acid labile and the acid resistant active ingredient. Consequently, the kit of parts of the present invention when administered according to the invention provides improved bioavailability of both the acid-resistant and acid-labile active ingredient. | 02-18-2010 |
20100061972 | Method of Treating Peyronie's Disease - The invention is directed to methods of treating patients suffering from Peyronie's disease, methods of identifying patients suffering from Peyronie's disease and a computer program for identifying patients suffering from Peyronie's disease. | 03-11-2010 |
20100221237 | ENZYME DISRUPTION OF BACTERIAL BIOFILMS - Methods for treating patients in which damaged tissue or an indwelling prosthetic device or catheter has a bacterial biofilm growing thereon, to at least partially disrupt said biofilm, by administering at least one antibacterial enzyme that is lethal or damaging to the biofilm-forming bacteria in an amount that is effective to at least partially disrupt the biofilm upon contact therewith. Methods for prophylactically treating a patient, and methods for disinfecting or sterilizing a surface ex-vivo to remove a biofilm or prevent biofilm growth are also disclosed, as well as implantable articles susceptible to biofilm growth to which a prophylactic coating of an antibacterial enzyme has been applied. | 09-02-2010 |
20100233150 | REDUCTION OF ADIPOSE TISSUE - The amount of adipose tissue, including lipomas, at selected locations in the body is reduced by introducing collagenase or collagenase plus another proteinase into the tissue. | 09-16-2010 |
20100233151 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 09-16-2010 |
20100247512 | Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue - Methods are provided for regulating fat storage, carbohydrate metabolism and fatty acid synthesis using modulators of membrane type matrix metalloproteinase 1 (MT1-MMP). | 09-30-2010 |
20100247513 | TREATMENT OF CARPAL TUNNEL SYNDROME BY INJECTION OF THE FLEXOR RETINACULUM - An apparatus and method for identifying the flexor retinaculum of the carpal tunnel, injecting an effective amount of an agent into at least a portion of flexor retinaculum or tissue adjacent thereto, wherein the agent is configured to weaken the flexor retinaculum. The system may further include means for increasing the tensile stress in the flexor retinaculum post-injection using hand exercises, thereby weakening its structural integrity and decreasing the pressure within the carpal tunnel that impairs median nerve function. | 09-30-2010 |
20100254970 | NGAL FOR REDUCTION AND AMELIORATION OF ISCHEMIC AND NEPHROTOXIC INJURIES - Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient. | 10-07-2010 |
20100330065 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 12-30-2010 |
20110044971 | METHOD AND COMPOSITION FOR TREATING A SERATONIN RECEPTOR-MEDIATED CONDITION - A method and composition for treating serotonin receptor-mediated conditions. | 02-24-2011 |
20110110922 | Wound Healing Peptides and Methods of Use Thereof - Methods and compositions for the treatment of wounds in a mammalian subject are provided. Particularly, novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation are provided. | 05-12-2011 |
20110171202 | METHOD OF TREATING HEARING LOSS USING XIAP - Disclosed is a method of treating or preventing hearing loss in a subject. The method comprises administering to the subject in need thereof, an adeno-associated viral expression vector encoding X-linked inhibitor of apoptosis protein (XIAP). The XIAP is positioned in the vector for expression in an inner ear organ, or associated neural structures, of the subject so as to treat or prevent the hearing loss. Also disclosed is a method of treating or preventing impaired balance. | 07-14-2011 |
20110189162 | Modified Clostridial Toxins Comprising an Integrated Protease Cleavage Site-Binding Domain - The present specification discloses modified Clostridial toxins, compositions comprising an integrated protease cleavage site-binding domain, polynucleotide molecules encoding such modified Clostridial toxins and compositions comprising di-chain forms of such modified Clostridial toxins. | 08-04-2011 |
20110189163 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 08-04-2011 |
20110217287 | Therapeutic composition comprising a botulinum neurotoxin - A pharmaceutical preparation comprising one of the botulinum neurotoxins from | 09-08-2011 |
20110229455 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS - The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions. | 09-22-2011 |
20110243919 | Compositions and Methods for Treating Collagen-Mediated Diseases - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 10-06-2011 |
20110243920 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 10-06-2011 |
20110311511 | CRYSTAL STRUCTURE OF PfA-M1 AND THE PfA-M1 Co4 COMPLEX - The invention relates to the X-ray crystal structure of PfA-M1 aminopeptidase alone, and in complex with the phosphinate dipeptide analogue hPheP[CH | 12-22-2011 |
20120121573 | Treatment of Pulmonary Vascular Remodeling With Neprilysin - The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues. | 05-17-2012 |
20120141454 | Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases - The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a PDE-4 inhibitor, a PDE-5 inhibitor, a compound that elevates cGMP and/or PKG, a stimulator of guanylyl cyclase and/or PKG, a combination of a compound that elevates cGMP, PKG or NO with an antioxidant that decreases ROS, or a compound that increases MMP activity. | 06-07-2012 |
20120148562 | METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS ASSOCIATED WITH VASCULAR HYPER-REACTIVITY - The present invention provides a methods and compositions for treating a patient having a skin condition characterized by vascular hyper-reactivity, such as chronic or episodic flushing or blushing, and/or rosacea. The method comprises applying a topical composition to affected areas of the patient's skin. The topical composition comprises an effective amount of a botulinum neurotoxin for decreasing vasodilation in cutaneous microvasculature, and a carrier for effectively transporting the botulinum toxin to the cutaneous microvasculature. The invention thereby provides a safe, effective, comfortable, and/or convenient manner of treating vascular hyper-reactivity in skin. | 06-14-2012 |
20120148563 | Method for Treating Premature Ejaculation with a Botulinum Neurotoxin - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided. | 06-14-2012 |
20120156189 | SKIN COSMESIS TREATMENT WITH CLOSTRIDIA NEUROTOXINS - Methods of using clostridial toxins and other biological agents to treat skin cosmesis in humans is provided. The disclosed methods provide beneficial effects in humans. | 06-21-2012 |
20120164131 | MODIFIED MUTANT COLLAGENASE AND IT'S USE IN FAT MELTING AND IN SCAR REDUCTION | 06-28-2012 |
20120189610 | TREATMENT OF PAIN - Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. | 07-26-2012 |
20120195878 | PROTOCOL FOR THE ADMINISTRATION OF BOTULINUM TOXINS - Embodiments of the invention provide treatment methods utilizing | 08-02-2012 |
20120207742 | Treatments Using PSMA Ligand Endopeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a prostate cancer, a benign prostatic hyperplasia, and/or neovascularization or pathological angiogenesis associated with a cancer in a mammal using such TVEMP compositions. | 08-16-2012 |
20120207743 | Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions. | 08-16-2012 |
20120237496 | PROTEASE VARIANTS - The present invention relates to polypeptides comprising protease variants of wild type human neprilysin having an altered specificity and/or activity. In particular the present invention relates to polypeptides comprising protease variants derived from human neprilysin having an increased specificity and/or activity against certain substrates, in particular against amyloid beta. | 09-20-2012 |
20120237497 | COMPOSITIONS AND METHODS FOR PRODUCING CLOSTRIDIAL COLLAGENASES - The present invention provides a method for producing a drug product comprising a combination of highly purified collagenase I and collagenase II from | 09-20-2012 |
20120282241 | Method of Treating Persistent Genital Arousal Disorder with a Neurotoxin - A method of controlling dysregulation of the dorsal cutaneous nerve of the clitoris and, in particular, a method for treating PGAD is provided. In one aspect, the method comprises administering a neurotoxin, such as a botulinum toxin, to the clitoral area of the human in need of treatment. | 11-08-2012 |
20120282242 | COMPOSITIONS, TARGETS, METHODS AND DEVICES FOR THE THERAPY OF OCULAR AND PERIOCULAR DISORDERS - Methods for treating ocular and periocular disorders by administration to a human patient of a therapeutically effective amount of a compound that modulates muscle action. | 11-08-2012 |
20120294844 | Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions - This invention relates to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances. | 11-22-2012 |
20120321612 | SYSTEMS AND METHODS FOR TREATING POST-OPERATIVE, ACUTE, AND CHRONIC PAIN USING AN INTRA-MUSCULAR CATHETER ADMINISTRATED COMBINATION OF A LOCAL ANESTHETIC AND A NEUROTOXIN PROTEIN - Systems, and methods for the use of such systems, are described that allow for the administration of a combination of a sustained release local anesthetic compound (such as bupivicaine) through a catheter based administration device and direct visualization or percutaneous injection of a neurotoxic protein compound (such as botulinum toxin) for post-operative and refractory treated muscle pain and discomfort in patients having undergone spinal surgery and other muscle splitting or treatments aimed at improving muscle pain. The systems utilize specific catheter-based administration protocols and methods for placement of the catheter in association with muscles surrounding the spine and other anatomical sites within the patient. The utilization of an initial bolus of a specific combination of medications (local anesthetic compound and\or neurotoxic protein compound) followed by a dosage pump administration through the catheter is anticipated. A variety of local anesthetics (in addition to bupivicaine) and a number of different neurotoxin proteins (in addition to the Botulinum toxin) may be utilized in the medicament administration protocols described. | 12-20-2012 |
20130108614 | WOUND HEALING PEPTIDES AND METHODS OF USE THEREOF | 05-02-2013 |
20130121987 | THERAPEUTIC COMPOSITION WITH A BOTULINUM NEUROTOXIN - The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from | 05-16-2013 |
20130136732 | ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY - This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof. | 05-30-2013 |
20130142776 | BOTULINUM TOXIN TREATMENTS OF DEPRESSION - Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression. | 06-06-2013 |
20130142777 | BOTULINUM TOXIN TREATMENTS OF DEPRESSION - Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression. | 06-06-2013 |
20130171127 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE - The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue. | 07-04-2013 |
20130177548 | TREATING NEOPLASMS WITH NEUROTOXIN - The present invention provides a method of treating a neoplasm using a neurotoxin, preferably botulinum toxin. Neurotoxin administered around a neoplasm acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze neoplastic cells through efferent channels leaving the neoplasm to distant sites. The present invention also provides a method of administering botulinum toxin at sites distant from the neoplasm, thereby enhancing cellular and humoral immunologic functions, which further contribute to neoplastic cell death. Following administration of botulinum toxin around or distant to a neoplasm as described herein, local, regional, and distant spread of neoplastic cells is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other diseases that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV. | 07-11-2013 |
20130195838 | Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. | 08-01-2013 |
20130195839 | Polymer-Based Compositions and Conjugates of Antimicrobial Agents - Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions. | 08-01-2013 |
20130224180 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine. | 08-29-2013 |
20130236446 | TREATMENT OF MIGRAINE HEADACHE WITH DIFFUSION OF TOXIN IN NON-MUSCLE RELATED AREAS OF THE MOUTH - A method for treating a patient with migraine headache includes administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form. The administration includes intra-oral extramuscular injection of the neurotoxin in a foramina of the sphenopalatine ganglion for enabling diffusion of the neurotoxin to the ganglion with the administration being on the trigeminal cervical system, enabling axonal transport of the neurotoxin from distal to central sites. | 09-12-2013 |
20130287758 | Injectable Amino-Acid Composition - An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in conjunction with botulinum toxin and fillers to enhance their effectiveness and extend their usefulness. | 10-31-2013 |
20130287759 | COLLAGENASE G AND COLLAGENASE H COMPOSITIONS FOR THE TREATMENT OF DISEASES INVOLVING ALTERATIONS OF COLLAGEN - Compositions comprising collagenase G and collagenase H (in a ratio between 1:2.5 and 1:3.5), optionally formulated in hydrogels, and its uses as medicament for the treatment of diseases involving alterations of collagen, such as fibromatosis, palmar Dupuytren's contracture, La Peyronie's disease, Ledderhose's disease or retractable scars. | 10-31-2013 |
20130287760 | TREATMENT FOR DUPUYTREN'S DISEASE - Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-α antagonist. TNF-α antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence. | 10-31-2013 |
20130330320 | Methods for Treating Adhesive Capsulitis - The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the invention relates to methods of treating or preventing adhesive capsulitis, or frozen shoulder, in a patient in need of such treatment comprising injecting or otherwise delivering an effective amount of collagenase to the collagenous adhesions in the shoulder. The invention also relates to the use of collagenase in the manufacture of a medicament to treat adhesive capsulitis. | 12-12-2013 |
20130330321 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine. | 12-12-2013 |
20130330322 | Methods of Treating Skin Aging With Toll-Like Receptor 7 Agonists - A method of reducing the appearance of skin aging comprising the step of applying a topical composition to the skin of a human exhibiting one or more signs of skin aging selected from fine lines, wrinkles, decreased skin elasticity, decreased light reflection, uneven pigmentation (dyschromia), coarse texture, dryness, solar lentigos, seborrheic keratoses, decreased dermal thickness, and/or increased sebum production, wherein the composition consists essentially of a dermatologically acceptable carrier and a targeted immune response modifier selected the group consisting of: (i) a 5-amino thiazolo[4,5-d]pyrimidin-one compound; (ii) an 8-hydroxyadenine compound; (iii) an imidazo-1,5-napthyridine compound; (iv) a 2-substituted-8-oxodeazapurine; (v) methyl 2-(3-{[6-amino-2-butoxy-8-oxo-7H-purin-9(8H)-yl]methyl}phenyl)acetate; (vi) 2-(3-{[6-amino-2-butoxy-8-oxo-7H-purin-9(8H)-yl]methyl}phenyl)acetic acid; and (iii) methyl 2-(3-(((3-(6-amino-2-butoxy-8-oxo-7H-purin-9(8H)-yl)propyl)(3-(dimethylamino)propyl)amino) phenyl)acetate and (vii) 2-(3-(((3-(6-amino-2-butoxy-8-oxo-7H-purin-9(8H)-yl)propyl)(3-(dimethylamino)propyl)amino)phenyl)acetic acid. | 12-12-2013 |
20140010803 | HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY - The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a | 01-09-2014 |
20140017225 | METALLOPROTEINASE-9 OLIGOPEPTIDES AND THEIR THERAPEUTIC USE - The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides, SEQ ID wherein the matrix metalloproteinase oligopeptide is at least one of SEQ ID 7, 11, 12, 18 and 19 and combination thereof. These oligopeptides are bound to antibodies to create an immune response in the subject mammal against the matrix metalloproteinases of various diseases. The instance method is a means of therapeutic intervention against the disease spread created by the matrix metalloproteinases. Further use of these oligopeptide-antibody responses can be extended to any and all diseases that use the matrix metalloproteinases to aid in their pathogenicity. | 01-16-2014 |
20140030248 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine. | 01-30-2014 |
20140030249 | Pharmaceutical Compositions - The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder. | 01-30-2014 |
20140065130 | METHOD FOR TREATING PREMATURE EJACULATION WITH A NEUROTOXIN - Methods for treating premature ejaculation and prolongation of climax time in a patient in need thereof by local administration of a Clostridial neurotoxin, such as a botulinum toxin, are provided. | 03-06-2014 |
20140079686 | Methods For Treating Baldness And Promoting Hair Growth - The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth. | 03-20-2014 |
20140079687 | Suture line Administration Technique using Botulinum Toxins - The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull. | 03-20-2014 |
20140086900 | Lyophilized Preparation of Botulinum Toxin - There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed. | 03-27-2014 |
20140099298 | Botulinum toxin treatments of Depression - Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression. | 04-10-2014 |
20140105883 | Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds - Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases. | 04-17-2014 |
20140105884 | MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES - Disclosed herein are materials, means and methods for sustained release of therapeutic agents for topical treatments. In particular, disclosed are means and methods for topical treatment of diseases of internal body cavities by embedding therapeutic agents in a slowly degrading biocompatible mixture applied to affected tissue. | 04-17-2014 |
20140112908 | NON-PROTEIN STABILIZED CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS - A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol. | 04-24-2014 |
20140127186 | PHARMACEUTICAL COMPOSITION FOR TREATING SCARS ON THE SKIN, AND METHOD FOR TREATING SCARS ON THE SKIN USING SAME - The present invention relates to a pharmaceutical composition for treating scars on the skin, comprising a mixture of botulinum toxin and air. The mixture of botulinum toxin and air according to the present invention, when injected in the dermis, may temporarily removed the elasticity of the dermis and flatten out the depressed part of the scar, and thus enables elaborate intradermic resection and increases the therapeutic effects of lasers for treating pulsed dye laser or of fractional lasers. Thus, scars on the skin can be effectively improved through a one-time operation without negatively affecting the daily lives of patients. | 05-08-2014 |
20140127187 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST - Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anti cancer-associated fibroblast composition; and a method for treatment of cancer. | 05-08-2014 |
20140127188 | METHOD FOR TREATMENT OF ADIPOSE DEPOSITS - Embodiments of the invention include methods and compositions for treatment of adipose deposits. | 05-08-2014 |
20140140981 | METHOD FOR TREATING PREMATURE EJACULATION WITH A BOTULINUM NEUROTOXIN - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided. | 05-22-2014 |
20140140982 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES - Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. | 05-22-2014 |
20140140983 | METHOD FOR TREATMENT OF AUTONOMIC NERVOUS SYSTEM DISORDERS - Botulinum toxin, among other presynaptic neurotoxins is used for the treatment of autonomic nervous system disorders such as irritable bowel syndrome. The neurotoxin is delivered to target the sympathetic ganglion. Exemplary delivery is carried out by way of injection. | 05-22-2014 |
20140154237 | METHODS AND KITS FOR TOPICAL APPLICATION, REMOVAL, AND INACTIVATION OF THERAPEUTIC OR COSMETIC TOXIN COMPOSITIONS - This invention relates to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances. | 06-05-2014 |
20140170132 | PROPHYLATIC TREATMENT OF HERPES RECURRENCE - The present invention relates to methods for prophylactic treatment of Herpes recurrence with a Clostridial neurotoxin, such as a | 06-19-2014 |
20140170133 | ALTERATION OF PROTEOLYTIC CLEAVAGE OF BOTULINUM NEUROTOXINS - The present invention pertains to a polynucleotide encoding a modified neurotoxin polypeptide comprising a modified neurotoxin light chain and a heavy chain, said modified light chain having at least one modification conferring altered cleavage by calpain proteases. Further encompassed by the present invention are vectors and host cells comprising the polynucleotide of the invention as well as polypeptides encoded by the said polynucleotide. In addition, the invention relates to compositions comprising the polynucleotide, vector, host cell or polypeptide of the invention as a medicament. | 06-19-2014 |
20140178357 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS - The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions. | 06-26-2014 |
20140193393 | Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist - Methods of using an ET | 07-10-2014 |
20140193394 | TREATMENT OF CARPAL TUNNEL SYNDROME BY INJECTION OF THE FLEXOR RETINACULUM - An apparatus and method for identifying the flexor retinaculum of the carpal tunnel, injecting an effective amount of an agent into at least a portion of flexor retinaculum or tissue adjacent thereto, wherein the agent is configured to weaken the flexor retinaculum. The system may further include means for increasing the tensile stress in the flexor retinaculum post-injection using hand exercises, thereby weakening its structural integrity and decreasing the pressure within the carpal tunnel that impairs median nerve function. | 07-10-2014 |
20140199288 | PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM NEUROTOXIN - This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D. | 07-17-2014 |
20140205589 | NEW STABLE ANESTHETIC COMPOSITION FOR REDUCING SKIN REACTIONS - A composition is described with reduced degradation rate and/or improved stability of its components. The composition can alleviate or even annihilate cutaneous reactions and can include an emulsion with an oil phase and an aqueous phase, wherein the oil phase can be a eutectic mixture of at least one anesthetic compound and at least one adrenergic receptor agonist. Methods of using such a composition are also described. | 07-24-2014 |
20140205590 | BOTULINUM TOXIN TREATMENTS OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder. | 07-24-2014 |
20140219992 | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof - Provided herein are methods of using modified matrix metalloprotease (MMP) enzymes that exhibit regulated activity in the presence of calcium. The methods include conditionally controlling the activity of the MMPs through the use of calcium to treat fibrotic diseases or conditions involving a component of the extracellular matrix (ECM). | 08-07-2014 |
20140242063 | PHARMACEUTICAL COMPOSITIONS - The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder. | 08-28-2014 |
20140242064 | METHODS AND APPARATUS FOR DELIVERING A THERAPEUTIC AGENT TO NASOPHARYNGEAL MUCOSA TARGETS - A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a delivery device. Actuation of the foam generating mechanism entraps gaseous bubbles from the gas in the liquid thereby forming a foam. The therapeutic agent is dispersed in the foam which has an expanded configuration adapted to fill a nasopharyngeal space and deliver the therapeutic agent to the mucosa targets. The delivery device is for delivering the foam to the nasopharyngeal space. The foam may also have a collapsed configuration for removal from the nasopharyngeal space or for concentration of the therapeutic agent onto the mucosa. | 08-28-2014 |
20140242065 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 08-28-2014 |
20140271610 | COLLAGEN AND ALGINATE-BASED FORMULATIONS FOR HEMOSTASIS - The present invention relates to composition(s) comprising collagen, calcium ions and alginate, wherein the composition polymerizes in situ when contacted with blood. The composition may further comprise an erythrocyte aggregation agent and/or a platelet activation agent. The composition may be formulated into two separate formulations. The first formulation comprises collagen in a calcium-containing solution and a second formulation comprises an aqueous alginate solution. The two formulations can be mixed prior to the contact with blood or mixed coincident with the contact with blood. | 09-18-2014 |
20140271611 | SUBCUTANEOUS ADMINISTRATION OF ADAMTS13 - This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein. | 09-18-2014 |
20140271612 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase - The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid. | 09-18-2014 |
20140286930 | Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact with the Corresponding Antigen - A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp. | 09-25-2014 |
20140286931 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR - The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 09-25-2014 |
20140294803 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 10-02-2014 |
20140302007 | BOTULINUM TOXIN FORMULATION - neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the | 10-09-2014 |
20140302008 | STABLE FORMULATIONS OF BOTULINUM TOXIN IN HYDROGELS - The invention includes liquid formulations of | 10-09-2014 |
20140308266 | MODIFIED NEUROTOXINS WITH POLY-GLYCINE AND USES THEREOF - The present invention is concerned with modified neurotoxins. Specifically, it relates to a modified biologically active neurotoxin polypeptide comprising at least one poly-Glycine domain. Also contemplated is a polynucleotide encoding the modified neurotoxin polypeptide having a poly-Glycine domain fused to the N-terminus, to the C-terminus or to both of the heavy and/or light chain of the mature neurotoxin polypeptide, vector comprising it and a host cell comprising such a polynucleotide or a vector. Moreover, envisaged are the aforementioned compounds for use as a medicament for treating various diseases. | 10-16-2014 |
20140308267 | NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY - The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein said polypeptide comprises at least one E3 ligase recognition motif in the light chain, wherein said E3 ligase recognition motif is preferably a binding motif for the E3 ligase MDM2. The invention further pertains to polypeptides encoded by the polynucleotide of the invention as well as polypeptides comprising one or more amino acid substitutions. Further encompassed by the present invention are vectors and host cells comprising the said polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising said polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments. | 10-16-2014 |
20140322197 | METHODS FOR TREATMENT OF HIP AND GROIN PAIN ASSOCIATED WITH FEMOROACETABULAR IMPINGEMENT (FAI) - Methods for treating or alleviating symptoms associated with femoroacetabular impingement (FAI) by local administration of a clostridial derivative, such as a botulinum toxin, to the hip capsule and surrounding muscle. | 10-30-2014 |
20140335071 | Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV - The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production. | 11-13-2014 |
20140335072 | Method of Treating or Reducing EFP - The present invention is directed to a method of treating or reducing EFP in a patient comprising administering one or multiple low dose injections of collagenase to an area affected by EFP. The invention encompasses methods wherein the dose of collagenase per injection is between about 50 to about 200 ABC units and/or wherein the concentration of collagenase is between about 50 to about 2000 ABC units/milliliter (ml). | 11-13-2014 |
20140341882 | PHARMACEUTICAL PRODUCT FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE - The present invention provides a therapeutic agent for Alzheimer's disease. The therapeutic agent contains membrane vesicles (exosomes) of adipose tissue-derived mesenchymal stem cells, and the membrane vesicles (exosomes) contain neprilysin. Through the research by the inventors of the present invention, it was revealed that exosomes secreted by human adipose tissue-derived mesenchymal stem cells contain neprilysin, which degrades amyloid-β as a pathogenic protein of Alzheimer's disease. When exosomes secreted by human adipose tissue-derived mesenchymal stem cells were administered to the brains of Alzheimer's disease model mice, the generation of amyloid-β was inhibited. | 11-20-2014 |
20140377248 | METHOD FOR THE MANUFACTURING OF DI-CHAIN PROTEINS FOR USE IN HUMANS - This invention relates to a novel method for producing di-chain proteins for use in humans from single-chain precursors, including di-chain clostridial neurotoxins. The method comprises the step of expressing a nucleic acid sequence encoding a single-chain precursor comprising a thrombin-cleavage site and the step of cleaving the single-chain precursor with a human factor Xa or a human thrombin, particularly a human thrombin drug product authorized for human therapeutic use. The invention further relates to novel di-chain clostridial neurotoxins and nucleic acid sequences encoding such novel di-chain clostridial neurotoxins. | 12-25-2014 |
20140377249 | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID AND COLLAGENASE FOR THE TOPICAL TREATMENT OF WOUNDS, BURNS AND ULCERS - The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars. | 12-25-2014 |
20150010532 | Clostridium Histolyticum Enzymes and Methods for the Use Thereof - The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration. | 01-08-2015 |
20150010533 | BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS - Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder. | 01-08-2015 |
20150030584 | TRANSPORT PROTEIN WHICH IS USED TO INTRODUCE CHEMICAL COMPOUNDS INTO NERVE CELLS - The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by | 01-29-2015 |
20150056179 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS - The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium | 02-26-2015 |
20150064165 | DEVICES AND METHODS FOR REDUCING THE APPEARANCE OF CELLULITE - Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae. | 03-05-2015 |
20150064166 | Lyophilized Preparation of Botulinum Toxin - There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed. | 03-05-2015 |
20150064167 | METHOD FOR TREATING PREMATURE EJACULATION WITH A BOTULINUM NEUROTOXIN - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided. | 03-05-2015 |
20150079069 | METHODS FOR MODIFICATION OF TISSUES - Methods for modification of mechanical properties or a shape of a mammalian tissue, excluding scar, blood clot, fat; including a step of contacting the tissue with an isolated eukaryotic endopeptidase in an amount sufficient to cause a modification of mechanical properties of the tissue or its shape, but insufficient to cause degradation of the tissue's into incohesive parts, and to the use of eukaryotic endopeptidases for use in methods for treatment of the mammalian body. | 03-19-2015 |
20150086531 | METHODS FOR MODIFYING PROGRESSION OF OSTEOARTHRITIS - Methods for modifying progression of osteoarthritis by local administration of a clostridial derivative, such as a botulinum toxin, to an arthritis-affected site are disclosed herein. | 03-26-2015 |
20150086532 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - A method of treating major depression comprising the steps of: identifying a subject with one or more symptoms of a depressive disorder; and administering a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of depression. | 03-26-2015 |
20150086533 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - A method of treating anxiety disorder comprising the steps of: identifying a subject with one or more symptoms of an anxiety disorder; a botulinum toxin to soft tissues outside the neurocranium using an injection selected from the group consisting of: a transdermal injection; a subcutaneous injection; and a percutaneous injection; and thereby reducing at least one symptom of anxiety disorder. | 03-26-2015 |
20150093373 | TREATMENT OF PULMONARY VASCULAR REMODELING WITH NEPRILYSIN - The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues. | 04-02-2015 |
20150104439 | PHARMACEUTICAL REMOVAL OF NEURONAL EXTENSIONS FROM A DEGENERATING DISC - The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically. | 04-16-2015 |
20150132281 | VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE - A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R | 05-14-2015 |
20150132282 | TREATMENT OF SOCIAL ANXIETY DISORDER, OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER USING BOTULINUM TOXIN - Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be | 05-14-2015 |
20150132283 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin. | 05-14-2015 |
20150147313 | ANIMAL PRODUCT-FREE CULTURE MEDIUM FOR BACTERIA OF THE GENUS CLOSTRIDIUM AND A PROCESS FOR PRODUCING SUPERNATANT COMPRISING ONE OR MORE COLLAGENOLYTIC AND GELATINOLYTIC PROTEASES - The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus | 05-28-2015 |
20150290302 | METHOD OF TREATING DEPRESSION - Methods are disclosed herein for treating depression in the subject. A method includes the use of | 10-15-2015 |
20150290303 | HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY - The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a | 10-15-2015 |
20150297787 | ANTIMICROBIAL COMPOSITION COMPRISING PYROGENIC SILICA AND SERRATHIOPEPTIDASE AND USES THEREOF - Methods are provided for treatment of wounds using a complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Pyrogenic silica is used as a siliceous sorbent, and serrathiopeptidase as a drug. | 10-22-2015 |
20150306003 | Injectable Amino-acid Composition - An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in conjunction with botulinum toxin and fillers to enhance their effectiveness and extend their usefulness. | 10-29-2015 |
20150306188 | TREATMENT OF HEADACHE BY INJECTION OF NEUROINHIBITORY SUBSTANCE TO SPHENOPALATINE GANGLION OR OTIC GANGLION - A neuroinhibitory substance for use in a method for treating or preventing headache comprising injecting a neuroinhibitory substance such as botulinium toxin in close proximity to the sphenopalatine ganglion or otic ganglion wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically and the neuroinhibitory substance injected in close proximity to the SPG or OG. | 10-29-2015 |
20150313973 | FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION - Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed. | 11-05-2015 |
20150313974 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 11-05-2015 |
20150320845 | System and Method for Modulation of Cardiac Tissue - The present invention provides compositions, systems, and methods for modulation of cardiac tissue. In one embodiment, the invention provides for bioenzymatic ablation of cardiac tissue. In certain embodiments, the present invention provides for application of collagenase or other therapeutic agents to digest targeted cardiac tissue. | 11-12-2015 |
20150328293 | PHARMACEUTICAL COMPOSITION COMPRISING BOTULINUM, A NON IONIC SURFACTANT, SODIUM CHLORIDE AND SUCROSE - The invention relates to a solid or liquid pharmaceutical composition comprising botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G), and a surfactant. In particular the invention relates to a solid or liquid pharmaceutical composition comprising a crystalline agent. | 11-19-2015 |
20150343036 | METHODS FOR REDUCING THE OCCURRENCE OR PREVENTING FORMATION OF BLADDER CALCULI - Methods for reducing the occurrence or preventing formation of bladder calculi associated with bladder augmentation or bladder reconstruction. | 12-03-2015 |
20150344861 | MUTANTS OF STREPTOKINASE AND THEIR COVALENTLY MODIFIED FORMS - The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates. Disclosed herein are site-specific biologically active conjugates of Streptokinases and its covalently modified variants. | 12-03-2015 |
20150374805 | USE OF BOTULINUM TOXIN THERAPY FOR TREATMENT OF UROLOGICAL NEUROLOGICAL CONDITIONS - The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | 12-31-2015 |
20160000889 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 01-07-2016 |
20160000890 | THERMOSENSITIVE HYDROGEL COLLAGENASE FORMULATIONS - It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase, which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pre-gelation, which would interfere with the ability to deliver the required dose for treatment. Still a further object of the disclosure is to provide a water-based topical formulation for collagenase which will be more compatible with other topically used medications to achieve better results. | 01-07-2016 |
20160008777 | PHARMACEUTICAL COMPOUNDING KIT | 01-14-2016 |
20160015656 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE - The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue. | 01-21-2016 |
20160015794 | Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease - A composition of botulinum toxin is claimed which can penetrate into the ocular surface inclusive of a penetration through a conjunctiva, cornea, and other structures. This composition allows for a maximal penetration of a topical preparation of botulinum toxin which serves to reduce the need for frequent allergy drops for the treatment of ocular surface disease and other conditions causing ocular surface inflammation or deep ocular inflammation. No puncture of the needle is necessary for the administration. Herein describes a novel composition using several principles based on composition, method of application, which enhances the effectiveness of the penetration. | 01-21-2016 |
20160030570 | FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION - Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed. | 02-04-2016 |
20160038395 | COMPOSITION FOR FACIAL CONTOURING COMPRISING MIXTURE OF BOTULINUM TOXIN AND AIR AND METHOD OF FACIAL CONTOURING USING THE SAME - The present invention provides a composition for facial contouring, comprising a mixture of botulinum toxin and air, and a method of facial contouring using the same. When the mixture of botulinum toxin and air is injected into an SMAS layer, the mixture strengthens the SMAS layer and draws back the galea aponeurotica to effectively lift up the face or change the facial contour, thus effectively enhancing the effect of facial contouring. | 02-11-2016 |
20160038396 | DERMAL FILLER - Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin. | 02-11-2016 |
20160045577 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - A method of treating circadian rhythm disorders includes identifying a subject with a circadian rhythm disorder or at least one symptom of a circadian rhythm disorder and administering an effective amount of a composition comprising a botulinum toxin and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of a circadian rhythm disorder. | 02-18-2016 |
20160051643 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin. | 02-25-2016 |
20160051644 | Botulinum Chimera Compositions for Axonal Regenerative Therapy During Spinal Cord Injury - The present invention relates to the isolation of polypeptides derived from the | 02-25-2016 |
20160051645 | Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds - Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases. | 02-25-2016 |
20160051646 | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS - Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described. | 02-25-2016 |
20160067319 | METHOD FOR TREATING PREMATURE EJACULATION WITH A BOTULINUM NEUROTOXIN - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided. | 03-10-2016 |
20160074454 | PHARMACEUTICAL COMPOSITION BASED ON CENTELLA ASIATICA (HYDROCOTYLE ASIATICA L.) FOR THE TREATMENT OF LOWER LIMB ULCERS - A pharmaceutical composition based on | 03-17-2016 |
20160074485 | METHODS FOR TREATING OSTEOARTHRITIS PAIN - Methods for alleviating osteoarthritis-associated symptoms by selecting a treatment-eligible patient and local administration of a clostridial derivative, such as a botulinum toxin, to an osteoarthritis-affected site are disclosed herein. | 03-17-2016 |
20160074486 | THERAPEUTIC COMPOSITION WITH A BOTULINUM NEUROTOXIN - The present invention pertains to pharmaceutical compositions which comprise botulinum toxin from | 03-17-2016 |
20160089442 | Lyophilized Preparation of Botulinum Toxin - There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed. | 03-31-2016 |
20160095908 | Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies - The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety, and sleep disorders and CNS disorders comprising the administration of a neurotoxin. | 04-07-2016 |
20160097044 | Antimicrobial Enzyme Fusions Reduce Resistance and Kill Intracellular Staphylococcus aureus - Multi-drug resistant bacteria are a persistent problem in modern health care, food safety and animal health. There is a need for new antimicrobials to replace over-used conventional antibiotics. Here we describe engineered triple-acting staphylolytic peptidoglycan hydrolases wherein three unique antimicrobial activities from two parental proteins are combined into a single fusion protein, effectively reducing the incidence of resistant strain development. The fusion protein reduced colonization by | 04-07-2016 |
20160106653 | Pharmaceutical Composition for Treating Scars on the Skin, and Method for Treating Scars on the Skin Using Same - The present invention relates to a pharmaceutical composition for treating scars on the skin, comprising a mixture of botulinum toxin and air. The mixture of botulinum toxin and air according to the present invention, when injected in the dermis, may temporarily removed the elasticity of the dermis and flatten out the depressed part of the scar, and thus enables elaborate intradermic resection and increases the therapeutic effects of lasers for treating pulsed dye laser or of fractional lasers. Thus, scars on the skin can be effectively improved through a one-time operation without negatively affecting the daily lives of patients. | 04-21-2016 |
20160114013 | PHARMACEUTICAL COMPOSITION COMPRISING A BOTULINUM NEUROTOXIN AND USES THEREOF - The invention relates a pharmaceutical composition containing botulinum toxin and a mucopolysaccharide uses thereof with increased pharmacological activity and long lasting botulinum toxin effect. | 04-28-2016 |
20160114015 | TREATMENT OF SOCIAL ANXIETY DISORDER, OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER USING BOTULINUM TOXIN - Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A. | 04-28-2016 |
20160145590 | CYTOLETHAL DISTENDING TOXIN SUBUNIT B CONJUGATED OR FUSED TO BACILLUS ANTHRACIS TOXIN LETHAL FACTOR - Disclosed is a protein comprising a cytolethal distending toxin subunit B (CdtB) conjugated or fused to a | 05-26-2016 |
20160151467 | COMPOSITION COMPRISING FILLER AND BOTULINUM TOXIN FOR ALLEVIATING SKIN WRINKLES OR AGING OR TREATING NEUROMUSCULAR DISEASES | 06-02-2016 |
20160151468 | Suture Line Administration Technique Using Botulinum Toxins | 06-02-2016 |
20160166658 | THERAPEUTIC INTERVENTION | 06-16-2016 |
20160168556 | UNGLYCOSYLATED LYSOSTAPHIN VARIANT PROTEIN | 06-16-2016 |
20160175407 | PROCESS FOR PREPARING A HIGHLY PURE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN AND USES THEREOF | 06-23-2016 |
20160175409 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS | 06-23-2016 |
20160175410 | SUSTAINED RELEASE POLOXAMER CONTAINING PHARMACEUTICAL COMPOSITIONS | 06-23-2016 |
20160184413 | FORMULATION FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENT - The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, wherein the formulation is free of stabilising proteins. | 06-30-2016 |
20160193213 | PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES | 07-07-2016 |
20160250302 | Compositions and Methods for Safe Treatment of Rhinitis | 09-01-2016 |
20160375112 | Reducing Adverse Side Effects of a Compound by a Neurotoxin - The present invention relates to methods and compositions for treating various side effects associated with the administration of one or more therapeutic compounds. In particular embodiments, the present invention relates to methods of reducing one or more adverse side effects associated with one or more therapeutic compounds by administering a neurotoxin, such as botulinum toxin, in combination with the one or more therapeutic compounds. | 12-29-2016 |
20170232080 | Treatment of Migraine Headaches with Presynaptic Neurotoxin | 08-17-2017 |
20190142912 | HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY | 05-16-2019 |
20220133646 | SOLUBILIZATE WITH CURCUMIN AND AT LEAST ONE CANNABINOID AS A FURTHER ACTIVE SUBSTANCE - In order to make available the health-promoting and healing properties of curcumin and/or cannabinoids to the human organism, the invention provides a solubilizate consisting of or comprising curcumin in a content equal to or less than 10 wt. %, and at least one cannabinoid as at least one further active substance, as well as at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids, and a solubilizate comprising, in particular consisting of at least one cannabinoid in a content of less than or equal to 10 wt. % and at least one emulsifier having an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids. | 05-05-2022 |
20220133682 | SOLUBILIZATE WITH CURCUMIN AND AT LEAST THE CANNABINOID THC AS A FURTHER ACTIVE SUBSTANCE - In order to make available the health-promoting and healing properties of curcumin and/or the cannabinoid THC to the human organism, the invention provides a solubilizate consisting of or comprising curcumin in a content equal to or less than 10 wt. %, and at least THC as at least one further active substance, as well as at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids, and a solubilizate comprising, in particular consisting of at least one cannabinoid in a content of less than or equal to 10 wt. % and at least one emulsifier having an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids. | 05-05-2022 |